These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27246782)

  • 1. Repurposing of Aspirin and Ibuprofen as Candidate Anti-Cryptococcus Drugs.
    Ogundeji AO; Pohl CH; Sebolai OM
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4799-808. PubMed ID: 27246782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward improved anti-cryptococcal drugs: Novel molecules and repurposed drugs.
    Krysan DJ
    Fungal Genet Biol; 2015 May; 78():93-8. PubMed ID: 25514636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F; Hare Jensen R; Meis JF; Arendrup MC
    Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
    Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copper Acyl Salicylate Has Potential as an Anti-Cryptococcus Antifungal Agent.
    Ogundeji AO; Porotloane BF; Pohl CH; Kendrekar PS; Sebolai OM
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29760146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibility of Cryptococcus gattii clinical isolates.
    Gomez-Lopez A; Zaragoza O; Dos Anjos Martins M; Melhem MC; Rodriguez-Tudela JL; Cuenca-Estrella M
    Clin Microbiol Infect; 2008 Jul; 14(7):727-30. PubMed ID: 18558948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii.
    Vu K; Gelli A
    Med Mycol; 2010 Mar; 48(2):255-62. PubMed ID: 19572230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluconazole alters the polysaccharide capsule of Cryptococcus gattii and leads to distinct behaviors in murine Cryptococcosis.
    Santos JR; Holanda RA; Frases S; Bravim M; Araujo Gde S; Santos PC; Costa MC; Ribeiro MJ; Ferreira GF; Baltazar LM; Miranda AS; Oliveira DB; Santos CM; Fontes AC; Gouveia LF; Resende-Stoianoff MA; Abrahão JS; Teixeira AL; Paixão TA; Souza DG; Santos DA
    PLoS One; 2014; 9(11):e112669. PubMed ID: 25392951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryptococcal therapies and drug targets: the old, the new and the promising.
    Coelho C; Casadevall A
    Cell Microbiol; 2016 Jun; 18(6):792-9. PubMed ID: 26990050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
    Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S
    J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluconazole resistance is not a predictor of poor outcome in patients with cryptococcosis.
    Vena A; Muñoz P; Guinea J; Escribano P; Peláez T; Valerio M; Bonache F; Gago S; Álvarez-Uría A; Bouza E
    Mycoses; 2019 May; 62(5):441-449. PubMed ID: 30184276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
    Chang WN; Huang CR; Lei CB; Lee PY; Chien CC; Chang HW; Chang CS; Lu CH
    Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
    Córdoba S; Isla MG; Szusz W; Vivot W; Altamirano R; Davel G
    Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
    Khyriem AB; Sujatha S; Parija SC
    Indian J Pathol Microbiol; 2006 Apr; 49(2):307-8. PubMed ID: 16933750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of antifungal combination against Cryptococcus spp.
    Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
    Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo.
    Butts A; Koselny K; Chabrier-Roselló Y; Semighini CP; Brown JC; Wang X; Annadurai S; DiDone L; Tabroff J; Childers WE; Abou-Gharbia M; Wellington M; Cardenas ME; Madhani HD; Heitman J; Krysan DJ
    mBio; 2014 Feb; 5(1):e00765-13. PubMed ID: 24520056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to therapy in patients with cryptococcosis and AIDS: Association with in vitro susceptibility to fluconazole.
    Agudelo CA; Muñoz C; Ramírez A; Tobón AM; de Bedout Bact C; Cano LE; Restrepo A
    Rev Iberoam Micol; 2015; 32(4):214-20. PubMed ID: 25637338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
    Nascimento E; Vitali LH; Kress MRVZ; Martinez R
    Rev Inst Med Trop Sao Paulo; 2017; 59():e49. PubMed ID: 28793019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.